The table below is a review of notable updates that occurred in June 2025 for investigational products in development (not an inclusive list). Click on the status to view our full coverage.

Rakovina Therapeutics Inc. ('Rakovina” or the 'Company”) (TSX-V: RKV) (FSE: 7JO0), a biopharmaceutical company advancing next ...

Acquires a highly selective and brain penetrant NLRP3 inhibitor from Mwyngil Therapeutics Company's lead candidate BT-267, a ...

Merck announced plans to acquire Verona Pharma for roughly $10 billion. 1 As part of the agreement between the two companies, Merck will add Verona’s COPD treatment Ohtuvayre to its cardio-pulmonary ...

Ultragenyx Pharmaceutical Inc. shares plunged 30% as UX143 trial raises efficacy doubts. Click for more on RARE and my ...

Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for ...

Amgen is dealing with the threat of several fast-approaching patent expirations. The drugmaker's dividend streak is impressive, and the stock is trading at reasonable levels. Amgen (NASDAQ: AMGN) ...

Merck to acquire respiratory drug maker, Verona Pharma for $10 billion: Rahway, New Jersey Thursday, July 10, 2025, 09:00 Hrs [IST] Merck, known as MSD outside of the United State ...

Investing.com -- Painreform Ltd (NASDAQ: PRFX) stock fell 11% following the company’s announcement of a strategic investment agreement with LayerBio Inc., a privately held Boston biotechnology company ...

Eli Lilly and Company’s LLY stock has declined 15.7% in the past year. The first-quarter earnings miss, guidance cut and some ...

API Innovation Center, founded in 2021, aims to secure domestic drug production. It's developing six molecules and expanding ...

The first phase of Fujifilm Biotechnologies’ $3.2-billion large-scale cell culture biopharmaceutical manufacturing plant in North Carolina is scheduled to begin operating this year.